Table 1 Patient characteristics at candidemia onset
Variables | Total cohort (n = 68) | 30-day survivors (n = 31) | 30-day non-survivors (n = 37) | P value |
|---|---|---|---|---|
Male sex | 47 (69.1) | 22 (71.0) | 25 (67.6) | 0.798 |
Age (years) | 68.0 (61.0–76.0) | 68.0 (58.0–76.0) | 68.0 (63.0–76.0) | 0.782 |
Time from hospital admission to onset (days) | 24.5 (8.0–46.5) | 20.0 (6.0–42.0) | 26.0 (9.0–47.0) | 0.479 |
APACHE II score (points) | 21.0 (18.0–26.0) | 19.0 (13.0–24.0) | 23.0 (19.0–27.0) | 0.003 |
Comorbidities and prior treatment exposure | ||||
Solid organ malignancy* | 11 (16.2) | 6 (19.4) | 5 (13.5) | 0.531 |
Hematological malignancy* | 2 (2.9) | 0 (0.0) | 2 (5.4) | 0.496 |
Solid organ transplantation | 4 (5.9) | 1 (3.2) | 3 (8.1) | 0.620 |
Hematopoietic stem cell transplantation | 1 (1.5) | 0 (0.0) | 1 (2.7) | 1.000 |
Liver disease | 14 (20.6) | 6 (19.4) | 8 (21.6) | 1.000 |
Diabetes mellitus | 14 (20.6) | 4 (12.9) | 10 (27.0) | 0.229 |
Autoimmune disease | 14 (20.6) | 7 (22.6) | 7 (18.9) | 0.769 |
Neutropenia (< 500 cells/mm3) | 2 (2.9) | 0 (0.0) | 2 (5.4) | 0.496 |
Abdominal surgery** | 18 (26.5) | 7 (22.6) | 11 (29.7) | 0.587 |
Invasive mechanical ventilation | 56 (82.4) | 23 (74.2) | 33 (89.2) | 0.124 |
Renal replacement therapy† | 23 (33.8) | 7 (22.6) | 16 (43.2) | 0.122 |
Total parenteral nutrition | 43 (63.2) | 18 (58.1) | 25 (67.6) | 0.458 |
Antibiotic therapy (for ≥ 3 days) † | 65 (95.6) | 30 (96.8) | 35 (94.6) | 1.000 |
Antifungal therapy (for ≥ 3 days) † | 6 (8.8) | 2 (6.5) | 4 (10.8) | 0.681 |
Immunosuppressive therapy† | 26 (38.2) | 9 (29.0) | 17 (46.0) | 0.211 |
Shock | 42 (61.8) | 17 (54.8) | 25 (67.6) | 0.324 |
Concurrent bacteremia | 22 (32.4) | 10 (32.3) | 12 (32.4) | 1.000 |
Breakthrough candidemia | 6 (8.8) | 2 (6.5) | 4 (10.8) | 0.681 |